Analysts expect that OptimizeRx Co. (NASDAQ:OPRX) will report $0.08 earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for OptimizeRx’s earnings. The highest EPS estimate is $0.10 and the lowest is $0.07. OptimizeRx posted earnings per share of $0.02 during the same quarter last year, which indicates a positive year over year growth rate of 300%. The company is scheduled to issue its next earnings results on Tuesday, August 6th.
According to Zacks, analysts expect that OptimizeRx will report full-year earnings of $0.41 per share for the current fiscal year, with EPS estimates ranging from $0.36 to $0.43. For the next financial year, analysts anticipate that the business will report earnings of $0.65 per share, with EPS estimates ranging from $0.55 to $0.74. Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for OptimizeRx.
Separately, Zacks Investment Research lowered Hess Midstream Partners from a “hold” rating to a “sell” rating in a research note on Tuesday, May 14th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $19.00.
In other news, major shareholder Awm Investment Company, Inc. sold 82,126 shares of the stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $13.64, for a total transaction of $1,120,198.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Several large investors have recently added to or reduced their stakes in OPRX. BlackRock Inc. purchased a new stake in shares of OptimizeRx during the fourth quarter valued at approximately $55,000. Westwood Management Corp IL purchased a new stake in shares of OptimizeRx during the first quarter valued at approximately $127,000. Bank of America Corp DE boosted its stake in shares of OptimizeRx by 15.8% during the fourth quarter. Bank of America Corp DE now owns 15,302 shares of the company’s stock valued at $168,000 after purchasing an additional 2,084 shares during the period. Northern Trust Corp boosted its stake in shares of OptimizeRx by 71.5% during the fourth quarter. Northern Trust Corp now owns 17,474 shares of the company’s stock valued at $192,000 after purchasing an additional 7,283 shares during the period. Finally, Tibra Equities Europe Ltd purchased a new stake in shares of OptimizeRx during the first quarter valued at approximately $338,000. 48.47% of the stock is owned by hedge funds and other institutional investors.
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Featured Story: How to invest in blue-chip stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.